|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Men constituted 60.4%; median patient age and tumor size at the initiation of imatinib were 58.6 (14.6-85.5) years and 51 (0-324) mm, respectively, without differences between periods except for older age and less preimatinib surgery in period 2.
|
30693663 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Histone deacetylase inhibitors induce the expression of tumor suppressor genes Per1 and Per2 in human gastric cancer cells.
|
30008892 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Animal studies and histopathological analysis identified that Per2 expression in A549 cells not only markedly increased expression of tumour anti‑oncogenes Bax, P53 and P21 but also inhibited expression of pro‑oncogenes vascular endothelial growth factor, CD44 and c‑Myc.
|
30226549 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, these results show that PER2 through the regulation of the numerous important downstream tumor-related genes, plays a major role in tumor suppression, and it may be a novel molecular target for cancer treatment.
|
28535015 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It thus appears that Per2 is an important inhibitor of tumor growth that acts by increasing TP53 expression, DNA damage repair, and apoptosis.
|
27036047 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, exogenous Per2 was successfully and stably expressed in nude mice tumor tissue samples.
|
27082164 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Having adjusted for age, adjuvant therapy and tumor stage, we evidenced that patients with higher PER2 and lower SIRT1 expression levels showed lower mortality (p = 0.028).
|
25798752 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Pairwise correlations between functionally-related clock genes (e.g., PER2-PER3 and CRY2-PER3) were stronger in ER+, HER2- and low-grade carcinomas; whereas, weaker correlation coefficients were observed in ER- and HER2+ tumors, high-grade tumors and tumors that progressed to metastatic disease.
|
25485508 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Among these genes, Per2 is reported to have tumor suppressor properties, but little is known about the correlation between Per2 and HIF, which is the main target of renal cell carcinoma (RCC) therapy.
|
25333958 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, our findings clearly demonstrate the tumor suppression function of PER2 and elucidate a pathway by which hypoxia promotes EMT via degradation of PER2.
|
23836662 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of genes positively associated with per2 gene expression was dependent on tumor staging and changes were observed preferentially in cancer tissue.
|
24062075 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results show for the first time that C/EBPalpha with its associated direct core clock gene target, PER2, are highly deregulated in DLBCL, suggesting an important tumor suppressive pathway in the pathogenesis of this lymphoma entity.
|
22260161 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the tumor tissue of CRC patients, compared to their matched healthy mucosa, expression levels of ARNTL1 (p=.002), PER1 (p=.002), PER2 (p=.011), PER3 (p=.003), and CRY2 (p=.012) were lower, whereas the expression level of TIM (p=.044) was higher.
|
22080729 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Per2, a core clock gene with tumour suppresser function, is critical to clock function and to the regulation of cellular proliferation.
|
19106159 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mammalian Per2 is a core clock gene, the product of which suppresses cancer cell proliferation and tumor growth in vivo and in vitro.
|
19916834 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Five lines of evidence suggest that melatonin works via epigenetic processes: (1) melatonin influences transcriptional activity of nuclear receptors (ERalpha, GR and RAR) involved in the regulation of breast cancer cell growth; (2) melatonin down-regulates the expression of genes responsible for the local synthesis or activation of estrogens including aromatase, an effect which may be mediated by methylation of the CYP19 gene or deacetylation of CYP19 histones; (3) melatonin inhibits telomerase activity and expression induced by either natural estrogens or xenoestrogens; (4) melatonin modulates the cell cycle through the inhibition of cyclin D1 expression; (5) melatonin influences circadian rhythm disturbances dependent on alterations of the light/dark cycle (i.e., light at night) with the subsequent deregulation of PER2 which acts as a tumor suppressor gene.
|
18592373 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent studies suggested that Per2 behaves as a tumor suppressor gene in mice.
|
15985538 |
2005 |